Efficient Viral Transduction in Fetal and Adult Human Inner Ear Explants with AAV9-PHP.B Vectors.
AAV
AAV9-PHP.B
ampulla
cochlea
gene therapy
hair cell
hearing loss
inner ear
saccule
utricle
vestibular
Journal
Biomolecules
ISSN: 2218-273X
Titre abrégé: Biomolecules
Pays: Switzerland
ID NLM: 101596414
Informations de publication
Date de publication:
10 06 2022
10 06 2022
Historique:
received:
29
04
2022
revised:
03
06
2022
accepted:
07
06
2022
entrez:
24
6
2022
pubmed:
25
6
2022
medline:
28
6
2022
Statut:
epublish
Résumé
Numerous studies have shown the recovery of auditory function in mouse models of genetic hearing loss following AAV gene therapy, yet translation to the clinic has not yet been demonstrated. One limitation has been the lack of human inner ear cell lines or tissues for validating viral gene therapies. Cultured human inner ear tissue could help confirm viral tropism and efficacy for driving exogenous gene expression in targeted cell types, establish promoter efficacy and perhaps selectivity for targeted cells, confirm the expression of therapeutic constructs and the subcellular localization of therapeutic proteins, and address the potential cellular toxicity of vectors or exogenous constructs. To begin to address these questions, we developed an explant culture method using native human inner ear tissue excised at either fetal or adult stages. Inner ear sensory epithelia were cultured for four days and exposed to vectors encoding enhanced green fluorescent protein (eGFP). We focused on the synthetic AAV9-PHP.B capsid, which has been demonstrated to be efficient for driving eGFP expression in the sensory hair cells of mouse and non-human primate inner ears. We report that AAV9-PHP.B also drives eGFP expression in fetal cochlear hair cells and in fetal and adult vestibular hair cells in explants of human inner ear sensory epithelia, which suggests that both the experimental paradigm and the viral capsid may be valuable for translation to clinical application.
Identifiants
pubmed: 35740941
pii: biom12060816
doi: 10.3390/biom12060816
pmc: PMC9221426
pii:
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : NICHD NIH HHS
ID : P50 HD105351
Pays : United States
Références
Otolaryngol Head Neck Surg. 2016 Jan;154(1):150-6
pubmed: 26307578
Nat Biotechnol. 2017 Mar;35(3):280-284
pubmed: 28165475
Hear Res. 2020 Sep 1;394:107882
pubmed: 31980281
Mol Ther. 2016 Feb;24(1):17-25
pubmed: 26307667
Otol Neurotol. 2012 Apr;33(3):473-80
pubmed: 22377650
Mol Ther Methods Clin Dev. 2018 Nov 20;13:1-13
pubmed: 30581889
J Clin Invest. 2018 Aug 1;128(8):3382-3401
pubmed: 29985171
Mol Ther. 2021 Mar 3;29(3):973-988
pubmed: 33212302
N Engl J Med. 2010 Oct 7;363(15):1438-50
pubmed: 20925546
Sci Transl Med. 2015 Jul 8;7(295):295ra108
pubmed: 26157030
Hear Res. 2020 Sep 1;394:107947
pubmed: 32247629
Gene Ther. 2007 Aug;14(15):1121-31
pubmed: 17568767
J Clin Med. 2020 Jul 21;9(7):
pubmed: 32708116
Elife. 2018 Jul 18;7:
pubmed: 30019672
Proc Natl Acad Sci U S A. 2017 Sep 5;114(36):9695-9700
pubmed: 28835534
Nat Biotechnol. 2017 Mar;35(3):264-272
pubmed: 28165476
Neuron. 2012 Jul 26;75(2):283-93
pubmed: 22841313
Lancet. 2005 Mar 5-11;365(9462):879-90
pubmed: 15752533
Lancet Neurol. 2019 May;18(5):459-480
pubmed: 30879893